is semaglutide still on shortage list ends as FDA sets deadline for compounders FDA declares semaglutide (Ozempic/Wegovy) shortage

The most common skin reactions are injection site reactions occurring in 1.42.4% of patients using Ozempic or Wegovy, typically presenting as mild redness, itching, bruising, or swelling that resolves within a few days

Side effects Common side effects are related to the use of semaglutide and are usually gastrointestinal-related

Other GLP-1 options and their temperature profiles Tirzepatide, the dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound, has similar refrigeration requirements but may have slightly different heat tolerance based on its formulation

You might wonder, "How much should I take?" or "How quickly will the dose increase?" It's completely normal to have these questions

Several treatment options are available to lower glucose levels